Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Chemotherapy"" wg kryterium: Temat


Starter badań:

Tytuł :
MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Autorzy :
Shen H; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Yin J; Department of Medical Imaging, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, China.
Niu R; Department of Radiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lian Y; Department of Radiology, The First Affiliated Hospital of Zhengzhou University, China.
Huang Y; Department of Hematology, Chongqing General Hospital, University of the Chinese Academy of Sciences, China.
Tu C; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Liu D; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Wang X; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Lan X; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Yuan X; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Zhang J; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China. Electronic address: zhangjq_.
Pokaż więcej
Źródło :
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2022 Jun; Vol. 171, pp. 107-113. Date of Electronic Publication: 2022 Apr 21.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*/methods
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy/methods ; Chemotherapy, Adjuvant/methods ; Humans ; Magnetic Resonance Imaging ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/therapy ; Neoplasm Recurrence, Local/drug therapy
Czasopismo naukowe
Tytuł :
Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients.
Autorzy :
Zhou M; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Thompson TD; Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Lin HY; Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA.
Chen VW; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Karlitz JJ; Division of Gastroenterology, School of Medicine, Tulane University; Gastroenterologist Southeast Louisiana Veteran Health Care System, New Orleans, LA.
Fontham ETH; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Theall KP; Department of Global Community Health and Behavioral Sciences, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
Zhang L; Department of Public Health Sciences, Clemson University, Clemson, SC.
Hsieh MC; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Pollack LA; Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Wu XC; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA. Electronic address: .
Pokaż więcej
Źródło :
Clinical colorectal cancer [Clin Colorectal Cancer] 2022 Jun; Vol. 21 (2), pp. e62-e75. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Colonic Neoplasms*/pathology
Chemotherapy, Adjuvant ; Humans ; Neoplasm Staging ; Proportional Hazards Models ; Retrospective Studies
Czasopismo naukowe
Tytuł :
A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.
Autorzy :
Xiao L; E.N.T. Department, Southern University of Science and Technology Hospital, 6019 Liuxian Street, Xili Avenue, Shenzhen City, 518085, Nanshan District, China.
Kang W; E.N.T. Department, Southern University of Science and Technology Hospital, 6019 Liuxian Street, Xili Avenue, Shenzhen City, 518085, Nanshan District, China.
Liao J; E.N.T. Department, Southern University of Science and Technology Hospital, 6019 Liuxian Street, Xili Avenue, Shenzhen City, 518085, Nanshan District, China.
Li Y; E.N.T. Department, Southern University of Science and Technology Hospital, 6019 Liuxian Street, Xili Avenue, Shenzhen City, 518085, Nanshan District, China. .
Pokaż więcej
Źródło :
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2022 May; Vol. 279 (5), pp. 2441-2450. Date of Electronic Publication: 2021 Aug 19.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Cisplatin*
Induction Chemotherapy*/adverse effects
Nasopharyngeal Carcinoma*/drug therapy
Nasopharyngeal Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Deoxycytidine/analogs & derivatives ; Humans
Czasopismo naukowe
Tytuł :
Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.
Autorzy :
Li Y; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Tang T; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, 510440, China.
Xiao J; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Li B; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Yang W; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Xie S; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Du Y; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Respirology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Huang K; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. .; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. .
Nie D; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. .; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2022 Jul; Vol. 101 (7), pp. 1509-1522. Date of Electronic Publication: 2022 Apr 20.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Network Meta-Analysis ; Pioglitazone/therapeutic use ; Remission Induction ; Young Adult
Czasopismo naukowe
Tytuł :
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.
Autorzy :
Alrawashdh N; Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.; Department of Health Sciences, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Vraney J; The University of Arizona College of Pharmacy/Banner, University Medical Center Tucson, Tucson, AZ 85721, USA.
Choi BM; Center for Health Outcomes & PharmacoEconomic Research, University of Arizona, Tucson, AZ 85721, USA.
Almutairi AR; Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.; Drug Sector, Saudi Food & Drug Authority, Riyadh, 13513-7148, Saudi Arabia.
Abraham I; Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.; Center for Health Outcomes & PharmacoEconomic Research, University of Arizona, Tucson, AZ 85721, USA.; The University of Arizona Cancer Center, Tucson, AZ 85719, USA.; Clinical Translational Sciences, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.; Matrix45, Tucson, AZ 85743, USA.
McBride A; Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.; The University of Arizona College of Pharmacy/Banner, University Medical Center Tucson, Tucson, AZ 85721, USA.; Center for Health Outcomes & PharmacoEconomic Research, University of Arizona, Tucson, AZ 85721, USA.; The University of Arizona Cancer Center, Tucson, AZ 85719, USA.
Pokaż więcej
Źródło :
Future oncology (London, England) [Future Oncol] 2022 Jun; Vol. 18 (19), pp. 2381-2390. Date of Electronic Publication: 2022 Apr 28.
Typ publikacji :
Journal Article
MeSH Terms :
Chemotherapy-Induced Febrile Neutropenia*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/etiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Leukopenia*/chemically induced
Lung Neoplasms*/complications
Lung Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Filgrastim ; Granulocyte Colony-Stimulating Factor/adverse effects ; Humans ; Polyethylene Glycols ; Recombinant Proteins/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł :
The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.
Autorzy :
Hsieh MC; Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan; College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Wang CC; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.
Yang CC; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.
Lien CF; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.
Wang CC; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.
Shih YC; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Otolaryngology, E-Da Cancer Hospital, Kaohsiung, Taiwan.
Yeh SA; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Radiation Oncology, E-Da Hospital, Kaohsiung, Taiwan.
Hwang TZ; College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan. Electronic address: .
Pokaż więcej
Źródło :
Oral oncology [Oral Oncol] 2022 May; Vol. 128, pp. 105848. Date of Electronic Publication: 2022 Mar 29.
Typ publikacji :
Journal Article
MeSH Terms :
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/etiology
Induction Chemotherapy*
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy ; Humans ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/etiology
Czasopismo naukowe
Tytuł :
Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.
Autorzy :
Ma YE; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.
Liang X; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.
Liu LI; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Gao D; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Yang T; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Hoffman RM; AntiCancer Inc., San Diego, CA, U.S.A.; Department of Surgery, UCSD, San Diego, CA, U.S.A.
Xu J; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China; .; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5507-5515.
Typ publikacji :
Journal Article
MeSH Terms :
Chemotherapy, Cancer, Regional Perfusion*/adverse effects
Chemotherapy, Cancer, Regional Perfusion*/mortality
Neoadjuvant Therapy*/adverse effects
Neoadjuvant Therapy*/mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Stomach Neoplasms/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Female ; Gastrectomy ; Humans ; Lymph Node Excision ; Male ; Margins of Excision ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
Autorzy :
Bridgewater J; UCL Cancer Institute, London, United Kingdom.
Fletcher P; Cancer Clinical Trials Unit, Birmingham, United Kingdom.
Palmer DH; Molecular and Clinical Cancer Medicine, Liverpool, United Kingdom.
Malik HZ; University Hospital Aintree, Liverpool, United Kingdom.
Prasad R; Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom.
Mirza D; Birmingham Woman's and Children's NHS Trust, Birmingham, United Kingdom.
Anthony A; Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom.
Corrie P; Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom.
Falk S; University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Finch-Jones M; University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Wasan H; Imperial College Healthcare NHS Trust, London, United Kingdom.
Ross P; Guys and St Thomas's NHS Trust, London, United Kingdom.
Wall L; Western General Hospital, Edinburgh, United Kingdom.
Wadsley J; Weston Park Cancer Centre, Sheffield, United Kingdom.
Evans TR; University of Glasgow, Glasgow, United Kingdom.
Stocken D; Leeds Institute of Clinical Trials Research, Leeds, United Kingdom.
Stubbs C; Cancer Clinical Trials Unit, Birmingham, United Kingdom.
Praseedom R; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Ma YT; Institute of Immunology and Immunotherapy, Birmingham, United Kingdom.
Davidson B; Royal Free Hospital NHS Trust, London, United Kingdom.
Neoptolemos J; University of Heidelberg, Heidelberg, Germany.
Iveson T; University Hospital Southampton NHS Trust, Southampton, United Kingdom.
Cunningham D; Royal Marsden Hospital, London, United Kingdom.
Garden OJ; University of Edinburgh, Edinburgh, United Kingdom.
Valle JW; University of Manchester, Manchester, United Kingdom.
Primrose J; University of Southampton, Southampton, United Kingdom.
Pokaż więcej
Corporate Authors :
BILCAP study group
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Jun 20; Vol. 40 (18), pp. 2048-2057. Date of Electronic Publication: 2022 Mar 22.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Biliary Tract Neoplasms*/drug therapy
Adolescent ; Capecitabine ; Chemotherapy, Adjuvant ; Humans ; Prognosis
Czasopismo naukowe
Tytuł :
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
Autorzy :
Lachowiez CA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reville PK; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Furudate K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shpall E; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2022 May; Vol. 9 (5), pp. e350-e360.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Neoplasm, Residual ; Propensity Score ; Prospective Studies ; Sulfonamides
Czasopismo naukowe
Tytuł :
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
Autorzy :
Li WZ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Lv X; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Hu D; Department of Radiation Oncology, Center for Cancer Prevention and Treatment, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China.
Lv SH; Department of Ultrasound, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Liu GY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Liang H; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Ye YF; Clinical Research Design Division, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Yang W; Department of Radiation Oncology, Nanhai People's Hospital, the Sixth Affiliated Hospital of South China University of Technology, Foshan, China.
Zhang HX; Department of Radiation Oncology, Center for Cancer Prevention and Treatment, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China.
Yuan TZ; Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.
Wang DS; Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Lu N; Department of Medical Imaging, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Ke LR; Department of Medical Imaging, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Tang WB; Department of Radiation Oncology, Nanhai People's Hospital, the Sixth Affiliated Hospital of South China University of Technology, Foshan, China.
Tong LH; Department of Radiation Oncology, Nanhai People's Hospital, the Sixth Affiliated Hospital of South China University of Technology, Foshan, China.
Chen ZJ; Department of Radiation Oncology, Center for Cancer Prevention and Treatment, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China.
Liu T; Department of Radiation Oncology, Center for Cancer Prevention and Treatment, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China.
Cao KJ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Mo HY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Guo L; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Zhao C; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Chen MY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Chen QY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Huang PY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Sun R; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Qiu F; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Luo DH; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Wang L; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Hua YJ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Tang LQ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Qian CN; Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.
Mai HQ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Guo X; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Xiang YQ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Xia WX; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Pokaż więcej
Źródło :
JAMA oncology [JAMA Oncol] 2022 May 01; Vol. 8 (5), pp. 706-714.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*/adverse effects
Nasopharyngeal Neoplasms*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Capecitabine/adverse effects ; Chemoradiotherapy/adverse effects ; Cisplatin/therapeutic use ; Fluorouracil ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/pathology ; Neoplasm Recurrence, Local/drug therapy ; Paclitaxel/adverse effects
Czasopismo naukowe
Tytuł :
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma-Is This the New Standard of Care?
Autorzy :
Willis M; University of Texas Medical Branch, Galveston.; University of Texas MD Anderson Cancer Center, Houston.
Pokaż więcej
Źródło :
JAMA oncology [JAMA Oncol] 2022 May 01; Vol. 8 (5), pp. 715-716.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Humans ; Nasopharyngeal Carcinoma/drug therapy ; Standard of Care
Czasopismo naukowe
Tytuł :
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.
Autorzy :
Egawa-Takata T; Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan.; Department of Obstetrics and Gynecology, Osaka Police Hospital, Osaka, Japan.
Ueda Y; Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan.
Ito K; Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan.
Hori K; Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan.
Tadahiro S; Department of Obstetrics and Gynecology, Iwate Medical University, Shiwa, Japan.
Nagasawa T; Department of Obstetrics and Gynecology, Iwate Medical University, Shiwa, Japan.
Nishio S; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
Ushijima K; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
Koji N; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Enomoto T; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Kikuchi A; Department of Obstetrics and Gynecology, Niigata Cancer Center, Niigata, Japan.
Honma S; Department of Obstetrics and Gynecology, Niigata Cancer Center, Niigata, Japan.
Oishi T; Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
Shimada M; Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
Takei Y; Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke, Japan.
Fujiwara H; Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke, Japan.
Tanabe H; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.; Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa, Japan.
Okamoto A; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Nishio Y; Department of Obstetrics and Gynecology, Osaka Police Hospital, Osaka, Japan.
Yamada T; Department of Medical Innovation Data Coordinating Center, Osaka University Hospital, Suita, Japan.
Kimura T; Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2022 May; Vol. 113 (5), pp. 1693-1701. Date of Electronic Publication: 2022 Mar 10.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Endometrial Neoplasms*/drug therapy
Carboplatin/adverse effects ; Chemotherapy, Adjuvant ; Female ; Humans ; Neoplasm Staging ; Paclitaxel/therapeutic use
Czasopismo naukowe
Tytuł :
Improved risk prediction of chemotherapy-induced neutropenia-model development and validation with real-world data.
Autorzy :
Venäläinen MS; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Heervä E; Department of Oncology, Turku University Hospital and FICAN West, Turku, Finland.; University of Turku, Turku, Finland.
Hirvonen O; Department of Oncology, Turku University Hospital and FICAN West, Turku, Finland.; Department of Clinical Oncology, University of Turku, Turku, Finland.; Palliative Center, Turku University Hospital, Turku, Finland.
Saraei S; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Suomi T; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Mikkola T; Tays Research Services, Clinical Informatics Team, Tampere University Hospital and University of Tampere, Tampere, Finland.
Bärlund M; Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Jyrkkiö S; Department of Oncology, Turku University Hospital and FICAN West, Turku, Finland.
Laitinen T; Department of Pulmonary Medicine, University of Turku and Turku University Hospital, Turku, Finland.; Administration Center, Tampere University Hospital and University of Tampere, Tampere, Finland.
Elo LL; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2022 Feb; Vol. 11 (3), pp. 654-663. Date of Electronic Publication: 2021 Dec 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents*/adverse effects
Chemotherapy-Induced Febrile Neutropenia*/diagnosis
Chemotherapy-Induced Febrile Neutropenia*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/etiology
Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Cohort Studies ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans
Czasopismo naukowe
Tytuł :
Targeted deep sequencing reveals APC mutations as predictors of overall survival in Chinese colorectal patients receiving adjuvant chemotherapy.
Autorzy :
Chen X; Department of General Surgery, Yangpu Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Hu M; Department of Pathology, Zhuji People's Hospital, Shaoxing, China.
Chen Y; Center for Clinical Research and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.; Institute of Gastrointestinal Surgery and Translational Medicine, Tongji University School of Medicine, Shanghai, China.
Li A; Department of General Surgery, Yangpu Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Hua Y; Center for Clinical Research and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.; Institute of Gastrointestinal Surgery and Translational Medicine, Tongji University School of Medicine, Shanghai, China.
Jiang H; Department of General Surgery, Yangpu Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Li H; Center for Clinical Research and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.; Institute of Gastrointestinal Surgery and Translational Medicine, Tongji University School of Medicine, Shanghai, China.
Lin M; Department of General Surgery, Yangpu Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.; Center for Clinical Research and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.; Institute of Gastrointestinal Surgery and Translational Medicine, Tongji University School of Medicine, Shanghai, China.
Pokaż więcej
Źródło :
Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2022 Apr; Vol. 57 (4), pp. 465-472. Date of Electronic Publication: 2022 Jan 03.
Typ publikacji :
Journal Article
MeSH Terms :
Adenomatous Polyposis Coli Protein*/genetics
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Fluorouracil*/administration & dosage
Chemotherapy, Adjuvant ; China ; High-Throughput Nucleotide Sequencing ; Humans ; Mutation ; Neoplasm Staging ; Prognosis
Czasopismo naukowe
Tytuł :
Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Autorzy :
Tao HY; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Zhan ZJ; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Qiu WZ; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Liao K; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Yuan YW; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Zheng RH; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Pokaż więcej
Źródło :
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Apr; Vol. 18 (2), pp. e111-e118. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article
MeSH Terms :
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy ; Cisplatin ; Docetaxel ; Fluorouracil/adverse effects ; Humans ; Nasopharyngeal Carcinoma/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Propensity Score ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.
Autorzy :
Liu X; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China.
Li WF; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China.
Ding C; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China.
Chen L; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China.
Sun Y; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China.
Li JH; Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510060, China.
Ma J; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China. Electronic address: .
Zhang Y; Department of Radiation Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou 510060, China. Electronic address: .
Pokaż więcej
Źródło :
Oral oncology [Oral Oncol] 2022 Feb; Vol. 125, pp. 105718. Date of Electronic Publication: 2022 Jan 18.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*/methods
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Body Mass Index ; Humans ; Nasopharyngeal Carcinoma/drug therapy ; Overweight ; Prospective Studies ; Randomized Controlled Trials as Topic ; Thinness/drug therapy ; Thinness/etiology
Czasopismo naukowe
Tytuł :
The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis.
Autorzy :
Liu T; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Dai S; Department of Medical Oncology, Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zhang H; Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Zhong X; Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Ding Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ma X; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
Head & neck [Head Neck] 2022 Feb; Vol. 44 (2), pp. 518-529. Date of Electronic Publication: 2021 Dec 04.
Typ publikacji :
Journal Article; Meta-Analysis; Review
MeSH Terms :
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bayes Theorem ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Fluorouracil/therapeutic use ; Humans ; Nasopharyngeal Carcinoma ; Network Meta-Analysis
Czasopismo naukowe
Tytuł :
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Autorzy :
Rovers KP; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.
Bakkers C; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.
Nienhuijs SW; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.
Burger JWA; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.
Creemers GM; Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands.
Thijs AMJ; Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands.
Brandt-Kerkhof ARM; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Madsen EVE; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
van Meerten E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Tuynman JB; Department of Surgery, Amsterdam University Medical Centers, location VUMC, Amsterdam, the Netherlands.
Kusters M; Department of Surgery, Amsterdam University Medical Centers, location VUMC, Amsterdam, the Netherlands.
Versteeg KS; Department of Medical Oncology, Amsterdam University Medical Centers, location VUMC, Amsterdam, the Netherlands.
Aalbers AGJ; Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kok NFM; Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Wiezer MJ; Department of Surgery, Sint Antonius Hospital, Nieuwegein, the Netherlands.
Boerma D; Department of Surgery, Sint Antonius Hospital, Nieuwegein, the Netherlands.
Los M; Department of Medical Oncology, Sint Antonius Hospital, Nieuwegein, the Netherlands.
de Reuver PR; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Bremers AJA; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Kruijff S; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
Witkamp AJ; Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
van Grevenstein WMU; Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Nederend J; Department of Radiology, Catharina Cancer Institute, Eindhoven, the Netherlands.
Lahaye MJ; Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kranenburg O; Cancer Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Fijneman RJA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
van 't Erve I; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hemmer PHJ; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
Dijkgraaf MGW; Department of Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
Punt CJA; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Tanis PJ; Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
de Hingh IHJT; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
Pokaż więcej
Corporate Authors :
Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group
Źródło :
JAMA surgery [JAMA Surg] 2021 Aug 01; Vol. 156 (8), pp. 710-720.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytoreduction Surgical Procedures*
Hyperthermic Intraperitoneal Chemotherapy*
Adenocarcinoma/*therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*pathology
Peritoneal Neoplasms/*therapy
Adenocarcinoma/secondary ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Capecitabine/administration & dosage ; Chemotherapy, Adjuvant/adverse effects ; Feasibility Studies ; Female ; Fluorouracil/administration & dosage ; Humans ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Mitomycin/administration & dosage ; Neoadjuvant Therapy ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin/administration & dosage ; Perioperative Period ; Peritoneal Neoplasms/secondary ; Response Evaluation Criteria in Solid Tumors
SCR Protocol :
Folfox protocol; IFL protocol
Czasopismo naukowe
Tytuł :
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
Autorzy :
Marks DI; United Bristol Healthcare Trust, Bristol, UK.
Kirkwood AA; CR UK and UCL Cancer Trial Centre, Cancer Institute, University College London, London, UK.
Rowntree CJ; Cardiff and Vale University Health Board, Cardiff, UK.
Aguiar M; University College London Cancer Institute, London, UK.
Bailey KE; University College London Cancer Institute, London, UK.
Beaton B; University College London Cancer Institute, London, UK.
Cahalin P; Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK.
Castleton AZ; The Christie NHS Foundation Trust, Manchester, UK.
Clifton-Hadley L; CR UK and UCL Cancer Trial Centre, Cancer Institute, University College London, London, UK.
Copland M; Paul O'Gorman Leukaemia Research Centre, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Goldstone AH; University College London Cancer Institute, London, UK.
Kelly R; St James's University Hospital, Leeds, UK.
Lawrie E; CR UK and UCL Cancer Trial Centre, Cancer Institute, University College London, London, UK.
Lee S; University College London Cancer Institute, London, UK.
McMillan AK; Centre for Clinical Haematology, Nottingham City Hospital, Nottingham, UK.
McMullin MF; Haematology, Queen's University, Belfast, UK.
Menne TF; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Mitchell RJ; University College London Cancer Institute, London, UK.
Moorman AV; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Patel B; Barts Cancer Institute, The London School of Medicine, Queen Mary University of London, London, UK.
Patrick P; CR UK and UCL Cancer Trial Centre, Cancer Institute, University College London, London, UK.
Smith P; CR UK and UCL Cancer Trial Centre, Cancer Institute, University College London, London, UK.
Taussig D; Haemato-Oncology Section, Royal Marsden Hospital, Sutton, UK.
Yallop D; King's College Hospital NHS Foundation Trust, London, UK.
Alapi KZ; University College London Cancer Institute, London, UK.
Fielding AK; University College London Cancer Institute, London, UK. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2022 Apr; Vol. 9 (4), pp. e262-e275.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Induction Chemotherapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Precursor Cells, B-Lymphoid ; Rituximab/adverse effects ; State Medicine ; Young Adult
Czasopismo naukowe
Tytuł :
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
Autorzy :
Sheth S; Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: .
Gilbert J; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Deal AM; Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chera B; Department of Radiation Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Murphy B; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Woods J; Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Miller K; Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Weissler M; Department of Otolaryngology-Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Hackman T; Department of Otolaryngology-Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Liao JJ; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Olson JG; Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Hayes DN; Division of Hematology-Oncology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Weiss J; Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Pokaż więcej
Źródło :
Oral oncology [Oral Oncol] 2022 Apr; Vol. 127, pp. 105807. Date of Electronic Publication: 2022 Mar 06.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Head and Neck Neoplasms*/drug therapy
Induction Chemotherapy*
Albumins ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/therapeutic use ; Cetuximab/therapeutic use ; Follow-Up Studies ; Humans ; Paclitaxel/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/drug therapy
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies